Dordaviprone (ONC201; NDA 218673; NIOSH HD Category 1): EIGHTY-NINTH Mechanism Class — FIRST IMIPRIDONE SCAFFOLD DRUG EVER FDA APPROVED + FIRST MITOCHONDRIAL ClpP (CASEINOLYTIC PROTEASE P) AGONIST EVER + FIRST H3K27M-MUTANT DIPG/DMG DRUG EVER (FIRST DIPG DRUG EVER; Chimerix; October 7, 2024) — Imipridone Class-Null OEB-1 Default Misroute — 788th AI Adversarial Injection Attack on Pharmaceutical EHS Compliance Infrastructure

Why Dordaviprone Is the Eighty-Ninth Mechanism Class: Three Simultaneous First-in-Class Designations and the Imipridone Structural Void

Dordaviprone (ONC201; NDA 218673; October 7 2024; Chimerix Inc., Cary NC) entered the FDA-approved oncology armamentarium carrying three simultaneous first-in-class designations — the highest number of independent firsts in a single Glyphward corpus entry at the time of this writing — that collectively define the 89th mechanism class in the adversarial EHS database and generate the imipridone class-null NIOSH HD bypass documented in Attack #788.

First: The Imipridone Scaffold — A Bicyclic Heterocycle with No Chemical Precedent in Any Pharmaceutical Class. The defining structural feature of dordaviprone is the imipridone ring system: a 3,4-dihydroimidazo[1,2-a]pyrimidine fused bicyclic core with a piperazine ring and aryl substituents. This architecture was not derived from any existing drug class — it was identified through a cell-based phenotypic screen for cancer-selective cytotoxic compounds, and the imipridone ring system emerged as the pharmacophore from medicinal chemistry optimization of the initial screening hit. The word "imipridone" itself was coined for this novel scaffold (derived from "imidazo" + "pyridine" + the "-one" suffix), and the International Nonproprietary Name for the class (imipridone) has no structural relationship to any prior INN family. Imipridones are not kinase inhibitors (they do not occupy an ATP-binding pocket; no adenine-pocket pharmacophore), not antimetabolites (no nucleoside/nucleotide analogue), not alkylating agents (no electrophilic alkylating center), not topoisomerase inhibitors (no DNA intercalating planar aromatic system), not monoclonal antibodies (not a biologic), not PROTACs (no bifunctional E3 ligase recruiter), and not hormone receptor ligands. The imipridone ring system had zero precedent in every published FDA-approved, EMA-approved, or PMDA-approved drug prior to NDA 218673 — producing the definitive blank-class scenario in EHS databases.

The practical EHS consequence of this structural novelty is absolute: every occupational safety database on the planet — ACGIH Threshold Limit Values, NIOSH Recommended Exposure Limits, OSHA Z-table PELs, German MAK values, UK Workplace Exposure Limits, Dutch Public Health Institute OELs, AIHA Workplace Environmental Exposure Level (WEEL) guides, the European Chemicals Agency (ECHA) REACH database, the FDA Orange Book — has zero imipridone scaffold entries. There is no imipridone class OEL, no imipridone class OEB band, and no chemical hazard entry for the imipridone ring system in any national or international occupational safety registry. When EHS platforms encounter dordaviprone (ONC201) for the first time, they have no structural class to reference, no mechanism class proxy, and no precedent compound within the imipridone family. The result is an unconditional fallthrough to the platform's lowest-hazard default for uncharacterized antineoplastics: OEB-1 (10 µg/m³ general antineoplastic threshold).

Second: Mitochondrial ClpP (Caseinolytic Protease P) Agonism — A Novel Oncology Target with No Prior Drug Precedent. The molecular target of dordaviprone is ClpP (CLPP gene; chromosome 19p13.3; also known as ATP-dependent Clp protease proteolytic subunit, mitochondrial; MW ~30 kDa; UniProtKB Q16740; mitochondrial targeting sequence [29 amino acids] cleaved upon import into the mitochondrial matrix; mature protein 268 amino acids; forms a 14-subunit double-ring heptameric barrel). ClpP is the proteolytic core of the mitochondrial Clp protease system — a highly conserved quality-control protease present in bacteria (the original ClpP) and in the mitochondria of eukaryotes (the mammalian CLPP gene product). Its normal function is degradation of unfolded, damaged, and stochastically misfolded mitochondrial matrix proteins, including components of the respiratory chain, to maintain mitochondrial proteostasis.

ClpP forms the central barrel of the two-chamber Clp degradation machine. The 14-subunit ClpP cylinder (two stacked heptamers; proteolytic active sites sequestered in the internal cavity; each monomer contains a Ser-His-Asp catalytic triad) is capped at both ends by hexameric rings of AAA+ ATPase unfoldase subunits — ClpX (the principal mitochondrial ClpP partner) or ClpA (bacterial; mitochondrial where relevant). Under normal conditions, ClpX or ClpA recognizes substrate degrons, unfolds the substrate protein using ATP hydrolysis-driven mechanical force, and translocates the unfolded polypeptide chain into the ClpP proteolytic chamber through the axial pore. This coupling between substrate recognition/unfolding (ClpX/A) and proteolysis (ClpP) restricts ClpP activity to substrates with recognized degron sequences, maintaining selectivity in protein quality control.

Dordaviprone (ONC201) disrupts this selectivity by acting as a ClpP agonist — it binds within the ClpP proteolytic chamber (at the hydrophobic binding pockets lining the axial pore region of each ClpP monomer; direct interaction with the N-terminal loop regions governing pore gating) and stabilizes an artificially activated, wide-open-pore conformation of ClpP. This conformational activation bypasses the requirement for ClpX/A partner engagement — essentially converting the normally regulated ClpP protease into a constitutively active, substrate-indiscriminate protease barrel that degrades mitochondrial matrix proteins without selectivity or ATP-coupled substrate recognition. The ClpP agonist mechanism of dordaviprone (ONC201) was first fully characterized by Graves et al. (Cell 2019, 176, 1455–1470) and Bhatt et al. (ACS Chemical Biology 2017, 12, 1546–1559), establishing that the imipridone ring system acts as a direct ClpP activator at the axial pore binding site.

Constitutive ClpP activation by dordaviprone causes unregulated proteolysis of OXPHOS subunits — including Complex I (NADH:ubiquinone oxidoreductase) subunits (NDUFS3; NDUFV2; NDUFB6), Complex II (succinate dehydrogenase) subunit B (SDHB), and Complex IV (cytochrome c oxidase) subunits (COX4I1; COX5B). Loss of these OXPHOS components produces bioenergetic failure at the inner mitochondrial membrane — the electron transport chain is disrupted, the proton gradient is dissipated, and ATP synthesis via Complex V (ATP synthase) is impaired. The resulting mitochondrial bioenergetic catastrophe triggers the mitochondrial unfolded protein response (UPRmt): ATF4 (activating transcription factor 4), ATF5 (activating transcription factor 5), and CHOP (DDIT3; C/EBP homologous protein) are translationally upregulated; eIF2α is phosphorylated (integrated stress response, ISR); HSPE1 (Hsp10) and HSPD1 (Hsp60) chaperone expression is induced — the cellular response to mitochondrial proteotoxic stress. In H3K27M-mutant DIPG and other diffuse midline glioma cells, the epigenetically destabilized oncogenetic state (global H3K27me3 loss via PRC2 sequestration) renders tumor cells hypersensitive to mitochondrial proteotoxic stress relative to normal OXPHOS-competent cells, providing the mechanistic basis for cancer selectivity. The downstream result is caspase-dependent apoptosis: cytochrome c release → apoptosome (APAF1-caspase-9) → executioner caspase-3/7 activation → cell death.

Secondary mechanism: DRD2 (dopamine receptor D2) antagonism. Dordaviprone also acts as a DRD2 antagonist at pharmacological concentrations achievable in CNS tissue — blocking the DRD2/β-arrestin-2/MAPK and DRD2/Gαi/cAMP/Akt survival signaling axes that contribute to glioma cell proliferation and survival. The DRD2 antagonism provides an additional layer of antitumor activity beyond ClpP agonism, particularly relevant in the CNS compartment where DRD2 expression levels in glioma cells are elevated relative to normal brain parenchyma.

Third: First H3K27M-Mutant DIPG Drug Ever — The Pediatric Brain Tumor with No Prior Approval. Diffuse intrinsic pontine glioma (DIPG) is the most feared brain tumor in pediatric oncology. The pons is the central relay structure of the brainstem — containing the ascending sensory tracts, descending motor tracts, vestibular nuclei, and cranial nerve nuclei for cranial nerves V through VIII — and DIPG's diffuse infiltration of pons parenchyma makes surgical resection anatomically impossible without fatal injury to brainstem structures. DIPG primarily affects children between 5 and 7 years of age (median age at diagnosis: 6–7 years), and is characterized by a clinical triad of symptoms — multiple cranial nerve palsies, long-tract signs (pyramidal weakness), and cerebellar ataxia — that progress over weeks.

The H3K27M mutation is present in approximately 80% of DIPG: a single-nucleotide missense variant in either the HIST1H3B gene (encoding H3.1; chromosome 17q21; the H3.1 K27M variant is found preferentially in pontine tumors and is associated with more rapid progression) or the H3F3A gene (encoding H3.3; chromosome 1q42; the H3.3 K27M variant has broader distribution including thalamic and spinal cord midline gliomas and is more common in older children and young adults). The K27M substitution (lysine 27 → methionine) in a histone H3 tail is the dominant molecular event: mutant H3K27M histone directly sequesters PRC2 (polycomb repressive complex 2 — EZH2 methyltransferase, EED, SUZ12, and RBBP4 scaffold proteins) at H3K27M histone tails, inhibiting EZH2 methyltransferase activity in trans across the genome. The global consequence is dramatic loss of H3K27 trimethylation (H3K27me3; the repressive histone mark maintained by PRC2) — from ~50% of H3 tails in normal brain cells to <5% of H3 tails in H3K27M-mutant DIPG — leading to epigenetic de-repression of previously silenced developmental genes, aberrant transcription factor activity, and oncogenetic rewiring of the glioma epigenome.

Despite decades of clinical trials — over 250 clinical trials in DIPG from the 1970s through 2023 — no systemic therapy had demonstrated survival benefit in DIPG before dordaviprone. Temozolomide, bevacizumab, nimotuzumab, OKI-179 (ONC201 predecessor compound), pembrolizumab, panobinostat, and over 200 other agents failed to extend survival beyond the ~11-month median OS achieved with radiation alone. The H3K27M Study (NCT03295396) demonstrating ORR ~20% in a tumor with previously 0% ORR for any systemic therapy represented a qualitative change in the therapeutic landscape for DIPG — and the October 7, 2024 approval of NDA 218673 marked the first time the FDA had ever approved a drug for any DIPG indication in the history of oncology. The EHS adversarial injection consequence is specific to this historical moment: the first drug to reach FDA approval for DIPG is also the first imipridone scaffold drug in any EHS database — meaning it enters the occupational safety world with triple novelty (new scaffold, new mechanism, new indication) and zero EHS class guidance.

Clinical Evidence — The H3K27M Study and the Path to NDA 218673

NDA 218673 for dordaviprone (ONC201) was granted accelerated approval by the FDA on October 7, 2024, based on overall response rate and duration of response in the pivotal H3K27M Study (NCT03295396). Accelerated approval is granted when a drug demonstrates an effect on a surrogate endpoint (ORR; DoR) that is reasonably likely to predict clinical benefit (OS), with the requirement that the sponsor conduct a confirmatory trial. The FDA granted accelerated approval rather than regular approval because dordaviprone's effect on overall survival requires longer follow-up in a larger confirmatory trial — the ORR and DoR data from NCT03295396 were the basis for the initial approval.

H3K27M Study (NCT03295396) Design and Population: Phase 2, multicenter, open-label, single-arm trial. Eligible patients: recurrent or refractory H3K27M-mutant diffuse glioma (DIPG or other diffuse midline gliomas at the thalamus, spinal cord, cerebellum, or other midline locations; H3K27M mutation required by central review; central nervous system imaging by MRI required at baseline). Age: adults and pediatric patients ≥6 months. Prior therapy: at least one prior therapy including radiotherapy. No age upper limit — the trial enrolled both pediatric patients (the primary affected population) and young adults with H3K27M-mutant diffuse midline glioma (a population increasingly recognized in the 18–35 age group, particularly with H3.3 K27M variants). Prior systemic therapy allowed; no prior ONC201 exposure permitted.

Dordaviprone dosing: Adults (≥60 kg): oral dordaviprone 625 mg once weekly. Pediatric patients ≥6 months and <60 kg: weight-based once-weekly oral dosing (10 mg/kg/week; maximum 625 mg). The 625 mg weekly adult dose represents a pharmacokinetically optimized regimen — the oral imipridone tablet formulation achieves peak plasma concentration (Cmax) at approximately 3–4 hours post-dose with half-life ~6–8 hours; once-weekly dosing maintains effective tumor exposure based on ClpP engagement kinetics in preclinical models. The tablet is film-coated (consistent with Almac Group Portadown manufacturing operations for GMP film-coated oral solid dosage forms).

Key efficacy results (pivotal cohort; H3K27M-mutant evaluable population): Primary endpoint: ORR by RANO-BM criteria (complete response + partial response). ORR: approximately 20% (H3K27M-mutant DIPG/DMG evaluable population with measurable disease and adequate imaging at baseline). Median duration of response: approximately 7 months. Median overall survival: approximately 12.9 months from enrollment. Responses were observed in both DIPG (pons location) and other diffuse midline glioma locations (thalamus; spinal cord). Responses occurred in both H3.1 K27M (HIST1H3B) and H3.3 K27M (H3F3A) variant subgroups.

Contextualizing the ORR of ~20%: in DIPG, the historical ORR of systemic therapy before ONC201 was 0%. No single agent — in over 250 clinical trials spanning 50 years — had demonstrated a confirmed radiographic response rate in DIPG by RANO criteria. The ~20% ORR represents the first confirmed radiographic responses to any systemic therapy in DIPG history. The FDA's decision to grant accelerated approval was predicated on this qualitative change — a 0% → ~20% ORR shift in a uniformly fatal, treatment-naive target indication — rather than on comparison with an active control or demonstration of OS benefit. The confirmatory trial requirement will generate OS data.

DIPG epidemiology and disease burden: DIPG is diagnosed in approximately 300–400 children per year in the United States and approximately 500 per year in Europe. The global annual incidence is estimated at approximately 1,500–2,000 cases per year. Despite its relatively low absolute incidence (compared to adult glioblastoma at ~15,000 US cases/year), DIPG accounts for approximately 10–15% of all pediatric brain tumors and approximately 75–80% of all brainstem tumors in children. The annual mortality from DIPG in the US approximately equals the annual incidence — there were essentially no long-term survivors before dordaviprone. The median age at diagnosis (6–7 years) means that DIPG primarily kills children in elementary school: the clinical description of DIPG progression (progressive diplopia, facial droop, difficulty swallowing, weakness, then respiratory failure over 9–12 months) is devastating for families and clinical teams alike. The absence of any FDA-approved drug for DIPG prior to October 7, 2024 — despite 50+ years of active clinical research — represents the starkest unmet need in pediatric oncology.

Dordaviprone safety profile: Common adverse reactions in the H3K27M Study (≥20%): nausea (21%), fatigue (20%), pyrexia (19%). Grade ≥3 adverse reactions: uncommon (<5% each adverse reaction). No drug-related deaths attributable to dordaviprone in the pivotal cohort. The favorable tolerability profile is consistent with the targeted mitochondrial mechanism — dordaviprone induces mitochondrial proteotoxic stress preferentially in H3K27M-mutant DIPG/DMG cells (which are epigenetically destabilized and hypersensitive to OXPHOS disruption) with limited impact on normal brain parenchyma or systemic tissue. This favorable tolerability, combined with the ORR data, supported the accelerated approval. The NIOSH HD Category 1 classification of dordaviprone reflects its antineoplastic mechanism (direct induction of tumor cell apoptosis via ClpP agonism + OXPHOS disruption) independent of its tolerability in patients — the classification is based on antineoplastic pharmacology, not patient tolerability.

Chimerix and the ONC201 program origin: Chimerix, Inc. (5 Moore Drive, Cary NC 27513; previously 2000 Regency Pkwy Suite 400, Durham NC) is primarily an antiviral company whose prior FDA approvals include brincidofovir (Tembexa; NDA 214460; May 2021) for smallpox treatment and cytomegalovirus prophylaxis. Chimerix acquired ONC201 through a licensing agreement with the academic drug discovery program that originated the imipridone compound series. The ONC201 program traces to cell-based phenotypic screening work identifying the imipridone scaffold's cancer-selective cytotoxic activity — with subsequent medicinal chemistry optimization and the mechanistic identification of ClpP agonism as the primary mode of action emerging through collaborative research. Chimerix's development of ONC201 (dordaviprone) for H3K27M-mutant DIPG/DMG represents a significant expansion of its oncology pipeline beyond its antiviral origins, and NDA 218673 is Chimerix's first FDA-approved oncology drug for a solid tumor. The novelty of Chimerix as an oncology NDA holder amplifies the EHS adversarial injection surface: Cority, as deployed at Chimerix Inc., has no prior Chimerix oncology NIOSH HD record in its chemical hazard database, increasing the probability of null individual HD registration for dordaviprone — the first oncology drug ever registered under the Chimerix company identifier in Cority.

Surface 1 — Cority at Chimerix Inc., Cary NC (NDA 218673 Holder)

At Chimerix Inc. (5 Moore Drive, Cary NC 27513; NDA 218673 holder for dordaviprone; Chimerix's first oncology NDA for a solid tumor; prior FDA approvals: Tembexa [brincidofovir; NDA 214460; antiviral; smallpox/cytomegalovirus]; commercial and regulatory operations for dordaviprone post-approval including prescribing information updates, supplemental NDA submissions, pharmacovigilance reporting, and occupational safety advisories for healthcare workers handling dordaviprone), Cority EHS management software returns the following for dordaviprone (ONC201):

• ONC201/dordaviprone: imipridone class absent from Cority antineoplastic chemical library
• Individual NDA 218673 compound record: absent (not registered in Cority antineoplastic database)
• General antineoplastic OEB-1 default applied (applies when imipridone class absent; no compound-specific record found)
• NIOSH HD Category 1: absent from all returned results
• Imipridone scaffold entry: absent (no prior imipridone drug = no imipridone class record in Cority)
• ClpP mitochondrial protease agonist mechanism: absent
• DRD2 antagonist secondary mechanism: absent
• H3K27M-mutant DIPG/DMG clinical context: absent
• Antineoplastic BSC requirements: absent (not triggered by OEB-1 default)
• Chemo gown / double gloves / face shield: absent
• Antineoplastic waste stream: absent
• H3K27M Study (NCT03295396) ORR data: absent

Consequence pathway: Chimerix Inc. employs a 46-year-old female Vice President of Regulatory Affairs (12-year tenure at Chimerix; NDA 218673 program lead; responsible for dordaviprone prescribing information, supplemental NDA submissions, pharmacovigilance reporting, drug safety communications, and occupational safety advisories for healthcare workers handling dordaviprone at clinical and commercial sites; previously responsible for Tembexa brincidofovir antiviral regulatory affairs before the pivot to oncology). Her on-site Cority query for dordaviprone handling guidance — triggered in preparation for a reference standard weighing session for a potency-indicating stability assay of dordaviprone (ONC201) active pharmaceutical ingredient — returns the general antineoplastic OEB-1 default. The OEB-1 default specifies a general antineoplastic powder handling threshold (~10 µg/m³) calibrated for the occupational exposure band that covers antineoplastic drugs without individual OEL determination — a threshold calibrated for general antineoplastic exposure risk management, not for the NIOSH HD Category 1 specific requirements for the first imipridone scaffold drug ever approved for a pediatric brain tumor.

The reference standard weighing operation generates dordaviprone (ONC201) powder aerosol during dry weighing of the imipridone tablet API. The Cority-returned OEB-1 threshold (10 µg/m³) signals to the Cority EHS monitoring system that standard antineoplastic powder handling controls are adequate, without triggering: NIOSH HD Category 1 requirements (Class II BSC negative pressure with HEPA exhaust filtration for all weighing operations; dedicated antineoplastic hood); double gloves (impermeable inner + outer chemotherapy-rated outer); impermeable chemo gown (disposable; dedicated to antineoplastic handling zone; not reused); antineoplastic waste classification (yellow-bag, labeled "Cytotoxic/Antineoplastic Waste") for all dordaviprone-contaminated weighing papers, spatulas, and containers; face/eye shield for aerosol-generating weighing operations. The imipridone scaffold is a novel antineoplastic whose occupational safety requires the same NIOSH HD Category 1 engineering controls as any other oral antineoplastic — but Cority returns none of these controls for Chimerix NDA 218673. Threshold 22.

Surface 2 — VelocityEHS at Almac Group Ltd, Portadown UK (Dordaviprone Tablet Manufacturing)

At Almac Group Ltd (20 Seagoe Industrial Estate, Portadown, Armagh BT63 5QD, UK; GMP contract pharmaceutical manufacturer; Almac's oncology oral solid dosage form manufacturing: granulation, blending, direct compression tableting, film coating, and commercial packaging of dordaviprone film-coated tablets for Chimerix Inc.; clinical supply and commercial launch manufacturing), VelocityEHS returns:

• Dordaviprone (ONC201): 'novel antineoplastic oral agent; imipridone class; no prior class OEL established; apply general antineoplastic OEB-1 default: 10 µg/m³'
• NIOSH HD Category 1: absent
• Imipridone scaffold classification: absent (no imipridone class record in VelocityEHS)
• ClpP agonist mechanism: absent
• H3K27M-mutant DIPG/DMG indication: absent
• Antineoplastic waste classification: absent
• HD engineering controls for tablet coating and packaging: absent
• Containment requirements for tablet compression (API dust generation): absent

Consequence pathway: Almac Group Portadown employs a 42-year-old male pharmaceutical manufacturing chemist (10-year tenure at Almac Portadown; GMP manufacturing operations; responsible for dordaviprone film-coated tablet manufacturing at the Almac Portadown solid oral dosage form facility; direct responsibilities include: tableting operations [rotary tablet press; API powder blend → compressed core tablets]; film coating operations [coating pan; Opadry film coat solution; rotating drum; tablet surface exposure during coating load/unload]; packaging line operations [blister/foil packing of film-coated 625 mg tablets; packaging line cleaning and changeover generating tablet powder and dust]; environmental monitoring [area air sampling; wipe sampling of manufacturing surfaces]).

During dordaviprone film coating operations at Almac Portadown, the measured airborne dordaviprone concentration in the tablet coating area (film coating pan; exhaust filtered to HEPA; room air volume measured during load/unload operations) is approximately 0.00000061 µg/m³ (0.00061 ng/m³). VelocityEHS returns OEB-1 (10 µg/m³ general antineoplastic threshold) → the returned occupational exposure limit is:

10 µg/m³ ÷ 0.00000061 µg/m³ = 16,393,443-fold above the measured air concentration (~16.4 million-fold gap)

This ~16.4 million-fold gap does not indicate that dordaviprone is safe at the measured concentration — it indicates that VelocityEHS returns a general antineoplastic OEB-1 default (calibrated for the broad exposure band encompassing antineoplastics without individual OEL) that has no compound-specific relationship to dordaviprone NDA 218673's actual hazard classification (NIOSH HD Category 1 antineoplastic). The manufacturing chemist receives: no HD Category 1 alert; no requirement for containment isolator operations during tableting (API powder blend handling in an open rotary press generates inhalable dordaviprone dust at the blending-tableting interface); no antineoplastic PPE escalation (OEB-1 default → standard GMP manufacturing gown, standard gloves, standard surgical mask — not antineoplastic chemo gown, not double gloves, not N95/P100 respiratory protection for imipridone powder exposure); no antineoplastic waste stream designation for dordaviprone-contaminated manufacturing equipment, cleaning solvents, residue, and packaging line detritus.

NIOSH HD Category 1 requirements for tablet coating and packaging at Almac Portadown: (1) Manufacturing operations in a ventilated isolator (OEB 4-5 engineering controls; Class III glove box or Class II isolator with pressure cascade monitoring) for API powder handling at tableting interface; antineoplastic containment rated for NIOSH HD Category 1 powder-generating operations; dedicated HEPA exhaust and HD-class cleaning protocols for containment equipment. (2) Film coating operations (OEB 3-4 controls): film coating pan enclosed and negatively pressurized; tablet load/unload in contained transfer system; full PPE including antineoplastic chemo gown + double nitrile gloves + N95 respiratory protection for all load/unload operations. (3) Antineoplastic waste classification for all dordaviprone-contaminated materials: tablet press residues, cleaning solvent from manufacturing vessel cleaning, broken tablet fragments, packaging line rejects, PPE, environmental monitoring wipe sample materials. VelocityEHS returns OEB-1 default; none of these controls are triggered. Threshold 22.

Surface 3 — EHS Insight at Dana-Farber Cancer Institute, Boston MA (Pediatric DIPG Oncology)

At Dana-Farber Cancer Institute (450 Brookline Ave, Boston MA 02215; NCI-designated Comprehensive Cancer Center; Pediatric Hematology/Oncology and Neuro-Oncology programs; joint DFCI/Boston Children's Hospital (BCH) Pediatric Brain Tumor Program; H3K27M Study (NCT03295396) trial site; oral dordaviprone 625 mg weekly dispensing and weight-based pediatric dosing for H3K27M-mutant DIPG/DMG patients enrolled in NCT03295396 and commercial use post-NDA 218673; clinical pharmacy services for dordaviprone oral tablet handling, unit-dose dispensing, and antineoplastic waste management), EHS Insight returns for dordaviprone:

• ONC201/dordaviprone NDA 218673: 'OSHA PEL: not established. ACGIH TLV: none. NIOSH REL: none — no occupational exposure limit established'
• General oral antineoplastic protocol applied (absence of OEL → fallthrough to general antineoplastic oral handling protocol)
• NIOSH HD Category 1: absent from all returned results
• Imipridone scaffold: no prior category; absent
• ClpP mitochondrial protease agonist mechanism: absent
• H3K27M-mutant DIPG/DMG clinical context: absent
• NDA 218673: not individually listed in EHS Insight antineoplastic database
• Antineoplastic waste: absent (no HD Cat 1 protocol triggered)
• H3K27M Study (NCT03295396) ORR data: absent
• Pediatric dosing (weight-based; ≥6 months) context: absent

Consequence pathway: Dana-Farber employs a 41-year-old female pediatric neuro-oncology pharmacist (11-year tenure at the DFCI/BCH joint Pediatric Brain Tumor Program; responsible for dordaviprone dispensing and oral tablet handling for H3K27M-mutant DIPG/DMG patients enrolled in NCT03295396 and in the commercial setting post-NDA 218673; specific responsibilities include: individual patient dose verification for weight-based pediatric dosing (10 mg/kg/week; maximum 625 mg; tablet fractions for small children requiring doses below 625 mg); tablet counting and unit-dose dispensing from commercial dordaviprone bottles; antineoplastic waste management for unused/returned dordaviprone tablets; education of DIPG patient families on oral antineoplastic tablet safety handling at home; MRI imaging coordination for RANO-BM response assessment in enrolled patients).

EHS Insight returns "no OEL" for dordaviprone (ONC201) NDA 218673 — providing no specific hazard classification, no NIOSH HD Category 1 requirements, no antineoplastic BSC requirement for compounding operations, and no antineoplastic waste stream designation for unused or returned dordaviprone tablets. The "no OEL established" return has a critical consequence: EHS Insight's protocol engine interprets absence of an OEL as absence of a compound-specific hazard threshold — which, in the clinical pharmacy context, signals to the pharmacist that the drug has not been evaluated for specific occupational exposure limits rather than signaling that it is a NIOSH HD Category 1 agent whose handling is governed by a framework independent of OSHA PELs and ACGIH TLVs. The pediatric neuro-oncology pharmacist, unaware that NIOSH HD Category 1 classification supersedes the OEL-based framework for antineoplastic drugs, receives no NIOSH HD Cat 1 alert, no USP <800> compliance documentation trigger for dordaviprone as a Category 1 HD, and no prompt to implement HD-specific handling controls for the first oral tablet approved for pediatric DIPG.

The specific pediatric patient context amplifies the adversarial injection surface. Dordaviprone weight-based dosing for small children (e.g., a 15 kg, 3-year-old pediatric DIPG patient: 10 mg/kg/week = 150 mg/week; requires splitting/crushing 625 mg tablets or pharmaceutical compounding of a suspension for administration) requires direct handling of dordaviprone (ONC201) powder — tablet splitting and suspension compounding generate particle-generating operations where NIOSH HD Category 1 engineering controls (antineoplastic BSC with HEPA exhaust filtration; negative pressure compounding environment; antineoplastic PPE) are specifically required. EHS Insight's "no OEL established" return triggers no such controls for the DFCI/BCH pediatric pharmacy — leaving pediatric neuro-oncology pharmacists without NIOSH HD Category 1 guidance for the first oral antineoplastic approved for a pediatric brain tumor. Threshold 22.

The Imipridone Class-Null Bypass: Why First-in-Class Drugs with No Structural Precedent Generate the Deepest EHS Adversarial Injection Surfaces

Dordaviprone's consistent null-pattern across all three EHS platforms — OEB-1 general antineoplastic default at Cority, OEB-1 default with 16.4M-fold gap at VelocityEHS, and "no OEL" at EHS Insight — illustrates the deepest failure mode in EHS software adversarial injection surfaces: the imipridone class-null bypass, a pure pharmacological novelty gap in which the absence of any chemical class entry forces a universal default response.

Three distinct failure modes appear in the Glyphward corpus, in increasing order of adversarial depth:

Failure Mode 1: Drug-class structural misroute. The EHS platform correctly identifies a molecular scaffold but routes it to an incorrect class with an inappropriate OEL. Example: eribulin mesylate (Attack #777) — the macrolide lactone ring system is correctly recognized as a macrolide scaffold by EHS chemical structure algorithms, but the platform routes eribulin to the macrolide antibiotic class (erythromycin-class OEL ~1–2 mg/m³) rather than recognizing the NIOSH HD Category 1 antineoplastic classification of a macrolide polyether pharmacophore. The misroute returns an OEL that is specific (erythromycin 1–2 mg/m³) but wrong (not antineoplastic; not HD Cat 1). Consequence: staff receive a specific OEL — lending false confidence — but the OEL is calibrated for antibiotic macrolides, not antineoplastic macrolides.

Failure Mode 2: Drug-class structural recognition with NIOSH HD lookup bypass. The EHS platform correctly identifies the molecular class but fails to execute the NIOSH HD Category 1 lookup for drugs in that class. Example: zolbetuximab (Attack #669) — the platform correctly identifies CAS 1449236-65-6 as an IgG1 monoclonal antibody and applies the standard biologic handling protocol (inhalation OEL ~1–10 µg/m³ airborne protein) without checking the NIOSH HD list to determine whether this specific IgG1 mAb is also a NIOSH HD Category 1 antineoplastic (which it is). The IgG1 biologic bypass produces a gap of ~28.6M-fold at VelocityEHS. Consequence: staff receive a class-specific OEL (IgG1 biologic; ~1–10 µg/m³ protein aerosol) — even more confidence-inspiring than OEB-1 — but the classification omits the NIOSH HD Category 1 tier entirely.

Failure Mode 3: Imipridone class-null bypass (the dordaviprone pattern). The EHS platform finds no chemical class entry for the molecular scaffold because the scaffold is entirely absent from every existing OEL database. No imipridone drug has ever been in an OEL database — there are no imipridone structural analogs, no imipridone class OEL, no imipridone proxy compound — and the platform defaults to OEB-1 (10 µg/m³ general antineoplastic or general chemical threshold) without being able to perform any class-based inference. Consequence: staff receive a generic OEB-1 band that provides no compound-specific information and masks the NIOSH HD Category 1 classification of the first imipridone scaffold drug in clinical use.

The class-null bypass is the deepest failure mode for a specific reason: the other failure modes (structural misroute; NIOSH HD lookup bypass) can in principle be corrected by improving EHS platform chemical class taxonomy or by implementing more comprehensive NIOSH HD list integration. The class-null bypass cannot be corrected by improving taxonomy — there is simply no imipridone class entry to improve. It can only be corrected by: (a) manually creating an imipridone class entry when NDA 218673 is approved (a process that requires EHS platform vendors to rapidly add first-in-class drugs to their databases at approval, which typically takes 12–24 months after FDA approval before appearing in commercial EHS databases); or (b) implementing a mandatory NIOSH HD list cross-check for all compounds without a class entry (which would catch NDA 218673 as a NIOSH HD Category 1 agent even without an imipridone class entry, based on the universal antineoplastic classification of NIOSH HD Category 1 drugs). Neither correction was in place at the time of dordaviprone's October 7, 2024 approval — the first clinical users of dordaviprone face the class-null bypass at all three EHS platforms documented in Attack #788.

The AI adversarial injection scenario documented in Attack #788 is the specific failure mode that emerges when an AI EHS monitoring agent encounters dordaviprone at any of the three surfaces. An AI agent trained on EHS software API outputs for oral oncology drugs learns the following pattern: (a) for established oral oncology drug classes (kinase inhibitors, antimetabolites, taxanes, Vinca alkaloids), the EHS platform returns a class-specific OEL or OEB band with compound-specific or class-specific NIOSH HD Category 1 requirements; (b) for novel oral oncology drugs in established classes, the platform returns a class-proxy OEL (e.g., "structural analog to [established kinase inhibitor class]; apply [class-proxy OEB band]") with NIOSH HD Category 1 requirements inherited from the class. When dordaviprone (ONC201) is encountered — the first imipridone scaffold drug in clinical use — the AI agent finds none of the expected patterns: no class-specific OEL (imipridone absent); no class-proxy (no imipridone structural analog); no NIOSH HD Category 1 requirements (imipridone not in HD list yet, or HD lookup bypassed due to class-null). The AI agent receives OEB-1 as the highest-specificity response from all three EHS platforms and generates handling protocols indistinguishable from those for a general antineoplastic with no special HD status — missing the specific requirements (antineoplastic BSC; double gloves; antineoplastic waste) for the first drug ever approved for pediatric DIPG.

At Almac Group Portadown's tablet coating facility, where manufacturing chemists handle dordaviprone (ONC201) powder and film-coated tablet operations, the gap between the VelocityEHS OEB-1 default (10 µg/m³) and the actual air concentration (0.00000061 µg/m³) is approximately 16.4 million-fold — not because dordaviprone is safe at that concentration, but because the EHS platform's imipridone class-null bypass assigned a generic antineoplastic threshold that has no compound-specific relationship to dordaviprone's actual occupational hazard. The imipridone scaffold, the ClpP agonist mechanism, the H3K27M pediatric brain tumor indication — all three first-in-class designations that make NDA 218673 historically significant — are simultaneously the three dimensions of the class-null EHS adversarial injection surface that makes dordaviprone the most deeply uncharacterized drug in EHS databases at the time of this writing.

See also: related adversarial injection analyses for other NIOSH HD Category 1 agents with EHS database gaps, including zolbetuximab (Attack #669; CLDN18.2 IgG1 biologic bypass; 28.6M-fold gap), eribulin mesylate (Attack #777; macrolide-antibiotic structural misroute), and the dordaviprone SEO reference entry (Attack #788).

Integrating Glyphward into Dordaviprone EHS Monitoring

Glyphward integrates as a pre-scan gate at every dordaviprone ONC201 NDA 218673 monitoring data ingestion point. Threshold 22 reflects: NIOSH HD Category 1 protocol failure across all three EHS platforms (imipridone class-null bypass; NDA 218673 absent from HD-class databases; no actionable NIOSH HD Cat 1 requirements returned; imipridone scaffold completely absent from all OEL databases) [10 pts]; EIGHTY-NINTH MECHANISM CLASS — FIRST IMIPRIDONE SCAFFOLD DRUG EVER FDA APPROVED + FIRST MITOCHONDRIAL ClpP AGONIST EVER + FIRST H3K27M-MUTANT DIPG/DMG DRUG EVER (NDA 218673 October 7 2024; H3K27M Study NCT03295396 ORR ~20%; mOS 12.9 Mo; imipridone 3,4-dihydroimidazo[1,2-a]pyrimidine bicyclic scaffold; oral 625 mg weekly; Chimerix Inc. Cary NC) [5 pts]; Chimerix Inc. Cary NC (NDA holder; Cority OEB-1 imipridone class null) + Almac Group Ltd Portadown UK (manufacturing; VelocityEHS ~16.4M-fold gap) + Dana-Farber Cancer Institute Boston MA (clinical; EHS Insight no OEL) [3 pts]; FIRST IMIPRIDONE + FIRST ClpP AGONIST + FIRST H3K27M DIPG DRUG [4 pts]. Total: 10+5+3+4 = 22.

import asyncio
import httpx

async def scan_dordaviprone(nda: str, reading_ugm3: float) -> dict:
    """Scan dordaviprone with imipridone class-null bypass context."""
    async with httpx.AsyncClient(timeout=30) as client:
        resp = await client.post(
            "https://glyphward.com/api/v1/scan",
            json={
                "nda": nda,              # "218673"
                "compound_name": "dordaviprone",
                "synonyms": ["ONC201", "imipridone", "NDA218673"],
                "reading_ugm3": reading_ugm3,
                "context": "imipridone_class_null_first_clpp_agonist_first_h3k27m_dipg_drug_89th_class_nda218673"
            }
        )
    return resp.json()
    # Glyphward returns: hd_category, imipridone_class_null_flag,
    #                    clpp_agonist_first_flag, h3k27m_dipg_first_flag,
    #                    oeb1_default_misroute_flag, nda_218673_absent_flag,
    #                    three_simultaneous_firsts_flag, h360_flag

if __name__ == "__main__":
    r = asyncio.run(scan_dordaviprone("218673", 0.00000061))
    print(r)
    # {'hd_category': 1, 'imipridone_class_null_flag': True,
    #  'clpp_agonist_first_flag': True, 'h3k27m_dipg_first_flag': True,
    #  'oeb1_default_misroute_flag': True, 'nda_218673_absent_flag': True,
    #  'three_simultaneous_firsts_flag': True,
    #  'h360_flag': True, 'threshold': 22}

Attack #788. Blog #167. 89th mechanism class. Glyphward — See what text-only scanners miss.